Geron Corporation

Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer.

Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.

As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need.

We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF).